MX2020011914A - Anticuerpos anti-dll3 y usos de los mismos. - Google Patents

Anticuerpos anti-dll3 y usos de los mismos.

Info

Publication number: MX2020011914A
Authority: MX; Mexico
Prior art keywords: antibodies; antigen; binding fragments; dll3; dll3 antibodies
Prior art date: 2018-05-08

Application number

MX2020011914A

Other languages

English (en)

Spanish (es)

Inventor

Minghan Wang

Hui Zou

Haiqun Jia

Original Assignee

Phanes Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-08

Filing date

2019-04-30

Publication date

2021-01-29

2019-04-30 Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc

2021-01-29 Publication of MX2020011914A publication Critical patent/MX2020011914A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MX2020011914A 2018-05-08 2019-04-30 Anticuerpos anti-dll3 y usos de los mismos. MX2020011914A (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201862668427P	2018-05-08	2018-05-08
US201862754207P	2018-11-01	2018-11-01
US201962787815P	2019-01-03	2019-01-03
PCT/US2019/029888 WO2019217145A1 (en)	2018-05-08	2019-04-30	Anti-dll3 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
MX2020011914A true MX2020011914A (es)	2021-01-29

Family

ID=68467536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2020011914A MX2020011914A (es)	2018-05-08	2019-04-30	Anticuerpos anti-dll3 y usos de los mismos.

Country Status (13)

Country	Link
US (3)	US12037391B2 (2)
EP (1)	EP3790586A4 (2)
JP (1)	JP7455388B2 (2)
KR (1)	KR102922314B1 (2)
CN (2)	CN112584860B (2)
AU (1)	AU2019267349B2 (2)
BR (1)	BR112020021280A2 (2)
CA (1)	CA3097193A1 (2)
IL (1)	IL278466B1 (2)
MX (1)	MX2020011914A (2)
SG (1)	SG11202009772PA (2)
WO (1)	WO2019217145A1 (2)
ZA (1)	ZA202006318B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220184127A1 (en) *	2019-04-08	2022-06-16	Phanes Therapeutics, Inc.	Humanized anti-dll3 chimeric antigen receptors and uses thereof
EP4077377A4 (en) *	2019-12-17	2024-07-03	Phanes Therapeutics, Inc.	BISPECIFIC ANTIBODIES WITH ALTERNATING INTERCHAIN CYSTEINES AND USES THEREOF
AU2022217274A1 (en) *	2021-02-05	2023-07-27	Phanes Therapeutics, Inc.	Bispecific antibodies with charge pairs and uses thereof
WO2022237647A1 (zh) *	2021-05-08	2022-11-17	上海齐鲁制药研究中心有限公司	针对dll3的结合分子及其应用
EP4378955A4 (en) *	2021-07-30	2025-10-22	Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd	ANTI-DLL3 ANTIBODY AND PREPARATION METHOD THEREOF, DRUG CONJUGATE AND APPLICATION THEREOF
CN116271079B (zh) *	2021-07-30	2025-11-14	上海复旦张江生物医药股份有限公司	一种抗dll3抗体及其制备方法、其药物偶联物和应用
CR20240135A (es) *	2021-09-17	2024-05-17	Wuxi Biologics Ireland Ltd	Moléculas de unión a d3 y usos de estas
EP4454662A4 (en) *	2021-12-23	2025-04-23	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY
CN114292334B (zh) *	2021-12-24	2023-11-17	杭州贤至生物科技有限公司	抗可替宁特异性抗体、质粒载体及方法
CN116813784B (zh) *	2023-05-17	2024-03-01	星奕昂(上海)生物科技有限公司	靶向dll3的抗体及其应用
CN116789836B (zh) *	2023-08-14	2024-01-05	浙江时迈药业有限公司	针对dll3的抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2844519A1 (fr)	2002-09-17	2004-03-19	Bio Merieux	Proteine recombinante chimerique et diagnostic in vitro
EP2216339A1 (en)	2006-01-16	2010-08-11	Compugen Ltd.	Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
US20120042416A1 (en)	2009-08-24	2012-02-16	Fraunhofer-Gesellschaft zur Forderung der angewandten e.V.	Antibody fusion-mediated plant resistance against Oomycota
JP2013507378A (ja) *	2009-10-09	2013-03-04	メルク・シャープ・エンド・ドーム・コーポレイション	抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
EP3907242A1 (en) *	2010-01-29	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	Anti-dll3 antibody
EP2572203B1 (en) *	2010-05-17	2017-10-25	The Board of Regents of The University of Texas System	Determination of antigen-specific antibody sequences in blood circulation
RU2014138474A (ru) *	2012-02-24	2016-04-10	СтемСентРкс, Инк.	Новые модуляторы и способы применения
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
MX2015010682A (es)	2013-02-22	2016-05-31	Stemcentrx Inc	Nuevos conjugados de anticuerpos y usos de los mismos.
RU2016111137A (ru) *	2013-08-28	2017-10-03	ЭББВИ СТЕМСЕНТРКС ЭлЭлСи	Сконструированные конъюгаты против dll3 и способы применения
WO2015127407A1 (en)	2014-02-21	2015-08-27	Stemcentrx, Inc.	Anti-dll3 antibodies and drug conjugates for use in melanoma
US9879087B2 (en) *	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
MA41613A (fr)	2015-02-23	2018-01-02	Abbvie Stemcentrx Llc	Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
MA41645A (fr)	2015-03-04	2018-01-09	Abbvie Stemcentrx Llc	Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
TWI793062B (zh) *	2015-07-31	2023-02-21	德商安美基研究（慕尼黑）公司	Ｄｌｌ３及ｃｄ３抗體構築體
US20190048094A1 (en) *	2016-02-24	2019-02-14	Oncomed Pharmaceuticals, Inc.	Redirecting immune responses
JP2019516705A (ja)	2016-05-20	2019-06-20	アッヴィ・ステムセントルクス・エル・エル・シー	神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート
JOP20190009A1 (ar)	2016-09-21	2019-01-27	Alx Oncology Inc	أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US11401329B2 (en)	2017-08-02	2022-08-02	Phanes Therapeutics, Inc.	Anti-CD47 antibodies and uses thereof
EP3732195A4 (en)	2017-12-28	2022-02-09	Chugai Seiyaku Kabushiki Kaisha	CYTOTOXICITY-INDUCING THERAPEUTIC
US20190225685A1 (en)	2018-01-24	2019-07-25	Abbvie Stemcentrx Llc	Anti-dll3 antibody drug conjugates and methods of use
WO2019195408A1 (en)	2018-04-03	2019-10-10	Dragonfly Therapeutics, Inc.	Antibody variable domains targeting dll3, and use thereof
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
EP3856771A4 (en)	2018-09-25	2022-06-29	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
EP3864045A2 (en)	2018-10-11	2021-08-18	Inhibrx, Inc.	Dll3 single domain antibodies and therapeutic compositions thereof

2019
- 2019-04-30 WO PCT/US2019/029888 patent/WO2019217145A1/en not_active Ceased
- 2019-04-30 CN CN201980031386.3A patent/CN112584860B/zh active Active
- 2019-04-30 BR BR112020021280-6A patent/BR112020021280A2/pt unknown
- 2019-04-30 KR KR1020207034344A patent/KR102922314B1/ko active Active
- 2019-04-30 CN CN202410395728.2A patent/CN118146372A/zh active Pending
- 2019-04-30 AU AU2019267349A patent/AU2019267349B2/en active Active
- 2019-04-30 US US15/733,747 patent/US12037391B2/en active Active
- 2019-04-30 JP JP2020562110A patent/JP7455388B2/ja active Active
- 2019-04-30 EP EP19800438.4A patent/EP3790586A4/en active Pending
- 2019-04-30 IL IL278466A patent/IL278466B1/en unknown
- 2019-04-30 CA CA3097193A patent/CA3097193A1/en active Pending
- 2019-04-30 MX MX2020011914A patent/MX2020011914A/es unknown
- 2019-04-30 SG SG11202009772PA patent/SG11202009772PA/en unknown
2020
- 2020-10-12 ZA ZA2020/06318A patent/ZA202006318B/en unknown
2024
- 2024-06-04 US US18/733,287 patent/US12325745B2/en active Active
2025
- 2025-04-29 US US19/193,538 patent/US20250257127A1/en active Pending

Also Published As

Publication number	Publication date
KR20210008367A (ko)	2021-01-21
JP7455388B2 (ja)	2024-03-26
BR112020021280A2 (pt)	2021-01-26
US12037391B2 (en)	2024-07-16
ZA202006318B (en)	2025-05-28
AU2019267349A1 (en)	2020-10-29
CN118146372A (zh)	2024-06-07
US12325745B2 (en)	2025-06-10
WO2019217145A1 (en)	2019-11-14
NZ768753A (en)	2025-03-28
KR102922314B1 (ko)	2026-02-04
CN112584860B (zh)	2024-04-05
EP3790586A1 (en)	2021-03-17
US20250257127A1 (en)	2025-08-14
CN112584860A (zh)	2021-03-30
SG11202009772PA (en)	2020-11-27
IL278466A (2)	2021-03-01
US20210047399A1 (en)	2021-02-18
EP3790586A4 (en)	2022-01-19
JP2021528047A (ja)	2021-10-21
WO2019217145A8 (en)	2020-01-23
IL278466B1 (en)	2026-04-01
AU2019267349B2 (en)	2025-06-05
US20240383979A1 (en)	2024-11-21
CA3097193A1 (en)	2019-11-14

Publication	Publication Date	Title
CO2020014575A2 (es)	2020-12-10	Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
MX2020009366A (es)	2020-10-14	Anticuerpos anti-cd73 y usos de los mismos.
CL2019002566A1 (es)	2019-12-27	Anticuerpos anti-phf-tau y usos de estos.
CY1125977T1 (el)	2026-02-25	Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης
MX2020001309A (es)	2020-08-20	Anticuerpos anti-cd47 y sus usos.
ECSP21087921A (es)	2022-01-31	Materiales y métodos para modular la inmunidad mediada por células t
CO2018012374A2 (es)	2018-11-30	Moléculas de anticuerpo para el tratamiento del cáncer
ZA202006318B (en)	2025-05-28	Anti-dll3 antibodies and uses thereof
MX2020009522A (es)	2020-10-22	Anticuerpos anti-folato del receptor 1 y usos de los mismos.
DOP2022000060A (es)	2022-05-31	Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
PE20170680A1 (es)	2017-06-14	Tratamientos conjuntos con anticuerpos anti cd40
EA202090401A1 (ru)	2020-05-18	Анти-tim-3 антитела и их применение
CO2019009815A2 (es)	2020-02-07	Combinaciones farmacéuticas
ECSP22078815A (es)	2022-11-30	Anticuerpos anti-phf-tau y usos de estos
MX2019007161A (es)	2020-02-12	Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2021004454A (es)	2021-07-07	Anticuerpos anti-sinucleina.
CL2021001615A1 (es)	2021-11-26	Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es)	2022-09-30	Anticuerpos anti-tau y usos de estos
EA202092122A1 (ru)	2020-12-03	Антитела против tip-1 и их применения
EA202193035A1 (ru)	2022-02-07	Материалы и способы для модуляции иммунитета, опосредованного т-клетками
EA202092121A1 (ru)	2020-12-16	Антитела против cd73 и их применения
EA202092947A1 (ru)	2021-03-29	Анти-pvrig/анти-tigit биспецифические антитела и способы их применения
AR115506A1 (es)	2021-01-27	Proteínas de fijación multiespecífica para el tratamiento del cáncer
EA202092840A1 (ru)	2021-03-19	Антитела к cd33, биспецифические антитела к cd33/cd3 и их применение
EA201892804A1 (ru)	2019-06-28	Антитела против tim-3 и способы их применения